Welcome To Viral Vector Formulation & Process Development Summit Europe!
Thank you to our speakers, sponsors and delegetaes who joined us in Amsterdam for the summit!
Emulating on the successful Viral Vector Process Development Summit in Boston, this summit was excited to connect thought leaders in CMC, Regulatory, Upstream and Downstream Processing in Europe this summer and address the unique challenges in this emerging market.
The Viral Vector Formulation & Process Development Summit Europe was the meeting that approached the most prominent challenges in the context of viral vector-based vaccine, gene and cell therapy process development in Europe.
Across 2 days, this summit helped attendees to benchmark their formulation, process development and understand reference materials against the most common vector candidates, navigate through the fast-evolving regulatory landscape and achieve a seamless scale-up.
They heard first-hand experience from the likes of Roche, VectorY, UCB, Boehringer Ingelheim and AviadoBio and many more to avoid common pitfalls:
- 2 main conference days packed with 14+ case studies with technical updates and 3 roundtable discussions to spark innovations and conversation
- 3 and a half hours of networking opportunities to interact with industry thought leaders and build meaningful relationships
This was a unique forum dedicated to viral vector process development professionals in Europe so clear 2 days of your agenda and be part of the conversation in 2024.
Our Viral Vector Process Development Community 2023 Attendees:
Testimonials from Viral Vector Process Development Summit in Boston:
“I loved the overall experience -great discussions and presentations. I learned new things and had the opportunity to network with the experts in the field.”
Senior Scientist, BioNTech AG
“The think tank atmosphere, high quality talks and networking opportunities made this a very successful event.”
Director of Translational Sciences, MEI Pharma
“Enjoyed the discussions, networking and collaboration opportunities.”
Senior Principal Scientist, Bristol Myers Squibb